This report was first published by Endpoints News. To see the original version, click here
YolTech Therapeutics, a prolific Chinese biotech that’s already begun testing four CRISPR gene editing therapies in small clinical studies, raised a $44.5 million Series B to test several more genetic medicines in humans and potentially begin its first Phase 3 trial later this year, it told Endpoints News in an exclusive interview.
The new round was led by the AstraZeneca-CICC Healthcare Investment Fund, a $1 billion equity fund established by the British pharma company and the China International Capital Corporation in 2019.
您已閱讀8%（620字），剩余92%（6931字）包含更多重要信息，訂閱以繼續(xù)探索完整內容，并享受更多專屬服務。